World Immunotherapy Congress - Agenda Day 2

 

World Immunotherapy Congress 2018, Day 2

08:00 Registration Opens

08:50 Conference doors open

Combination therapies

08:55

Chair's opening remarks

09:40

Title TBC

10:00

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297

10:20 Networking refreshment break

Oncology – immunotherapy for solid tumours

Manufacture, logistics and supply chain

Chaired by TBC

Chaired by TBC

Immunotherapy for solid tumours
11:45

T-SIGn viruses: systemic delivery of localised combination immuno-gene therapy within the tumour microenvironment

  • T-SIGn platform: transgene-bearing genetically modified variants of enadenotucirev, an oncolytic chimeric group B adenovirus with clinical data demonstrating virus delivery to tumours following systemic dosing
  • Up to 4 different transgenes have been encoded in a single virus, enabling the design of candidates expressing combinations of biological agents for targeted immunotherapy
  • Local production of therapeutic combinations by tumour cells infected with the T-SIGn virus enables high local production for increased activity while minimizing systemic exposure for improved safety
Manufacture, logistics and supply chain
11:45

Cell therapy supply chain management, logistics and scale out

  • Shipper suitability, features and options
  • Maintaining chain of custody for starting material and product
  • Logistics reliability and options
  • Supply chain sustainability and scale-out
Manufacture, logistics and supply chain
12:05

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Manufacture, logistics and supply chain
12:25

Development of endogenous and engineered TCR-T cell therapies for solid cancers

  • Immatics has a proprietary tumor antigen targets discovery platform, XPRESIDENT® which identifies tumor targets and screen TCRs against off-target toxicities
  • Endogenous and engineered TCRs against these tumor targets are used in Immatics’ Adoptive Cellular Therapy programs
  • IMA101 is a multi-product endogenous T cells against a warehouse of targets against various solid cancers currently in phase 1 clinical trial
  • IMA201, 202, and 203 are individual TCR engineered T cell products in various phase 1 trials for various solid cancers
  • Extensive process development was carried out using primary T cells derived from multiple healthy donors and cancer patients to optimize each step in the manufacturing of TCR T cells for 3 clinical trials (IMA101, IMA201, and IMA202)
  • Manufacturing for 3 trials in progress and a 4th is in progress
Immunotherapy for solid tumours
12:45

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Manufacture, logistics and supply chain
12:45

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297

Networking lunch

Oncology – combination therapy

Manufacture, logistics and supply chain

Chaired by TBC

Chaired by TBC

Combination therapy
14:35

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Manufacture, logistics and supply chain
14:35

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Combination therapy
14:55

Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial with metastatic melanoma patients treated with a soluble LAG-3 receptor (LAG-3lg or Eftilagimod Alpha) as an antigen pres

  • Understand the rationale for combining an APC activator (LAG-3lg or “efti”) with an immune checkpoint inhibitor (anti-PD-1 pembrolizumab)
  • Pharmacodynamic effects of efti (6 or 30 mg s.c.) in patients
  • Highlighting in vitro and in vivo preclinical data along with emerging clinical data
Manufacture, logistics and supply chain
14:55

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Combination therapy
15:15

IgA as novel antibody format for lymphoma and neuroblastoma is enhanced by myeloid checkpoint inhibitors

  • IgA recruits neutrophils as effector cells for treatment of cancer
  • Preclinical evidence for mode of action of IgA
  • Adverse effect for neuroblastoma treatment is eliminated with IgA
  • Blocking CD47/SIRPα axis strongly enhances IgA effects
Manufacture, logistics and supply chain
15:35

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297

15:55 Networking Break

Oncology - neoantigens

Immunotherapy for non-oncology

Chaired by TBC

Chaired by TBC

Neoantigens
17:00

Driving high T-cell titers to neoantigens in tumours – harnessing immunogenic viral vectors with immune check point modulators

  • DNA damage may cause mutations in tumours that can generate new antigens, known as tumour-specific neo-antigens (TSNAs)
  • Accurate prediction of TSNAs is key to generate potent TSNA specific vaccine approaches
  • Viral vector based vaccine platforms have shown to induce hi-titer, polyfunctional and durable CD4+ and CD8+ T-cell responses in humans
  • The personalized vaccine is delivered in combination with immune checkpoint blockade, to keep TSNA-induced T-cells active in the immunosuppressive tumour microenvironment
Immunotherapy for non-oncology
17:00

Targeting combined treatments to arthritic joints by antibody-specific to damaged cartilage: a safer therapy platform for rheumatoid arthritis

  • There are 40% of patients with rheumatoid arthritis that do not respond to treatments
  • A major issue with systemic treatment due to side effects
  • We developed a platform that can address these unmet needs by:
    • Targeting treatments to the disease tissue
    • Utilize the efficacy of combined biologics which could otherwise lead to major advert effects if administered systemically
Neoantigens
17:20

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Immunotherapy for non-oncology
17:20

Title TBC

Neoantigens
17:40

Development of a cost-effective personalized cancer neoantigen vaccines inducing a unique CD8-dominated T cell response

  • Potentiating vaccines by attracting, activating and delivering antigens to antigen presenting cells
  • Targeting results in a unique CD8-dominated T cell response.
  • DNA vaccine format allows a rapid, cost-effective and robust manufacturing process viable for manufacturing patient-specific vaccines on demand
  • A clinical study using targeted Vaccibody neoepitope DNA vaccines in multiple advanced cancer indications is ongoing
Immunotherapy for non-oncology
17:40

Proteomics crashes at the intersection of autoimmunity and cell biology

  • Review novel protein modifications that trigger autoimmune responses and pathology
  • Discuss proteins modifications that also alter cell biology and metabolism
  • Protein biomarkers as indicators of disease progression and therapeutic strategies
Neoantigens
18:00

Individualized therapeutic cancer vaccines – How to select for immunogenic neoantigens?

  • Selecting the right tumour specific antigens - the key for successful therapeutic T cell cancer vaccines
  • Bypassing prediction - identification of tumour specific T cell antigens by a functional readout
  • Vaccination with common tumour antigens - decoding the “Mutanome” presented on HLAs
Immunotherapy for non-oncology
18:00

Combinatorial therapeutic HIV-1 vaccines: Time for immune checkpoint inhibitors

  • Talk will focus on HIV-1 infected and treated patients who received therapeutic vaccination
  • Discuss the current work on how to improve therapeutic vaccination using immune checkpoint inhibitors
Neoantigens
18:20

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297

18:40 Poster presentation and networking drinks

last published: 20/Jul/18 13:45 GMT

 

Mark Your Calendars Now!
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October 

Sign Up for Event Updates